Skip to main content
SpringerLink
Log in

Kampagne der DGFF (Lipid-Liga) "Auf Ziel"

Kardiovaskuläre Hochrisikopatienten: Hilfe bei der LDL-C-Zielwerterreichung

  • Fortbildung
  • Published:
CardioVasc Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

© U. Makhmudova

Abb. 2

© DGFF (Lipid-Liga) e. V./Uniklinik Jena

Abb. 3

© U. Makhmudova

Literatur

  1. WHO Fact sheets 2021. Cardiovascular diseases (CVDs). https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

  2. Deutsche Herzstiftung. Deutscher Herzbericht 2020. https://www.herzstiftung.de/e-paper/#0

  3. Jernberg T, Hasvold P, Henriksson M et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36(19):1163-70

  4. Schubert J, Lindahl B, Melhus H et al. Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study. European Heart Journal. 2021;42(3):243-52

  5. Ray KK, Molemans B, Schoonen WM et al. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. European Journal of Preventive Cardiology. 2021;28(11):1279-89

  6. Allahyari A, Jernberg T, Hagström E et al. Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study. Eur Heart J. 2020;41(40):3900-9

  7. Schäfer A, Sanchez Martinez C, Flierl U et al. Standardized secondary prevention in patients with ST-elevation myocardial infarction. Eur J Prev Cardiol. 2020; https://doi.org/10.1093/eurjpc/zwaa078

  8. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769-818

  9. Toth P, Phan, Dayspring T. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012;8:415-27

  10. Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387-97

  11. Miettinen TA, Gylling H, Strandberg T, Sarna S. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. BMJ. 1998;316(7138):1127-30

  12. Sabatine MS, Giugliano RP, Keech AC et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-22

  13. Schwartz GG, Steg PG, Szarek M et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097-107

  14. Ray KK, Wright RS, Kallend D et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020;382(16):1507-19

  15. Bilen O, Ballantyne CM. Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase. Curr Atheroscler Rep. 2016;18(10):61

  16. Ballantyne CM, Laufs U, Ray KK et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiolog. 2020;27(6):593-603

  17. Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo (CLEAR Outcomes). https://clinicaltrials.gov/ct2/show/NCT02993406

  18. Ibanez B, James S, Agewall S et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39(2):119-77

  19. Ouchi Y, Sasaki J, Arai H et al. Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial. Circulation. 2019;140(12):992-1003

  20. Yu M, Liang C, Kong Q, Wang Y, Li M. Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature. Lipids Health Dis. 2020;19(1):1. https://doi.org/10.1186/s12944-019-1182-5

  21. Lütjohann D, Stellaard F, Mulder MT et al. The emerging concept of "individualized cholesterol-lowering therapy": A change in paradigm. Pharmacol Ther. 2019;199:111-6

  22. Hagiwara N, Kawada-Watanabe E, Koyanagi R et al. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. Eur Heart J. 2017;38(29):2264-76

  23. Weingärtner O, Sijbrands E, Lütjohann D. Letter by Weingärtner et al Regarding Article, "Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial". Circulation. 2020;141(6):e65-e66

  24. Weingärtner O, Sijbrands EJG, Lütjohann D. Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older. JAMA Cardiol. 2020;5(2):234

  25. Weingärtner O, Sijbrands EJG, Lütjohann D. Optimizing Clinical Cardiovascular Outcomes by a Personalized Approach to Add Ezetimibe to a Statin. J Am Coll Cardiol. 2020;75(1):128

  26. Weingärtner O, Patel SB, Lütjohann D. It's time to personalize and optimize lipid-lowering therapy. Eur Heart J. 2020;41(28):2629-31

  27. Fung V, Sinclair F, Wang H et al. Patients' perspectives on nonadherence to statin therapy: a focus-group study. Perm J. 2010;14(1):4-10

  28. Jackevicius CA. Adherence With Statin Therapy in Elderly Patients With and Without Acute Coronary Syndromes. JAMA. 2002;288(4):462

  29. Koenig W, Lorenz E, Beier L et al. Retrospective longitudinal analysis of prescription data to investigate real world adherence and persistence to lipid-lowering therapy in Germany. Clin Res Cardiol. 2021; https://doi.org/10.1007/s00392-021-01933-9; https://dgk.org/kongress_programme/ht2021/aP763.html

  30. O Weingaertner, L Beier, K Stein. Different perspectives of patients and physicians on LDL-C target achievement in the treatment of hypercholesterolemia: results on secondary prevention from the German PROCYON survey. ESC Congress 2021.

  31. Wood FA, Howard JP, Finegold JA et al. N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects. N Engl J Med. 2020;383(22):2182-4

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin I, Universitätsklinikum Jena, Am Klinikum 1, 07747, Jena, Deutschland

    Umidakhon Makhmudova &  P. Christian Schulze

  2. Klinikum Innenstadt d. LMU Münche, Med. Klinik u. Poliklinik IV/Stoffwechselambulanz, Ziemssenstraße 1, 80336, München, Deutschland

    Anja Vogt

  3. Klinik für Innere Medizin 1, Universitätsklinikum Jena, Am Klinikum 1, 07747, Jena, Deutschland

    Oliver Weingärtner

Authors
  1. Umidakhon Makhmudova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Christian Schulze
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anja Vogt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Oliver Weingärtner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Umidakhon Makhmudova.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Makhmudova, U., Schulze, P., Vogt, A. et al. Kardiovaskuläre Hochrisikopatienten: Hilfe bei der LDL-C-Zielwerterreichung. CV 21, 35–38 (2021). https://doi.org/10.1007/s15027-021-3603-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15027-021-3603-4

Search

Navigation